McKesson Corporation (NYSE:MCK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 10, Deutsche ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

If you are wondering whether McKesson still looks attractive after its strong run, or whether much of the potential upside is ...

McKesson saw strong 2025 growth from GLP-1 tailwinds, but fading momentum, weak margins, and a 21x forward P/E show ...

Discover why McKesson (MCK) is a Buy: strong revenue, margin gains, and robust capital returns suggest 13.5% upside. Click here to read my most recent analysis.

Healthcare giant McKesson Corp. on Tuesday said it will spin off its Technology Solutions unit and merge it with revenue cycle company Change Healthcare, creating a yet-to-be named healthcare services ...

McKesson trades at $825.38 and has moved in lockstep with the market. Its shares have returned 14.5% over the last six months ...

Deal Rationale McKesson’s strategic focus on disciplined portfolio management involves continuous evaluation of its business segments to ensure alignment with its growth priorities and optimize ...

McKesson Corporation is a major pharmaceutical distributor that offers health care supply chain management, retail pharmacy, oncology, specialty care and health care information technology services.

McKesson has entered into a definitive agreement to acquire CoverMyMeds, a developer of electronic prior authorization technology, for $1.1 billion or $0.9 billion net of cash incremental cash ...

McKesson is one of the largest healthcare companies on earth. It is known as a $264 billion revenue distributor of pharmaceuticals and medical supplies, but its business has much more breadth. The ...

In October, we joined forces with the Washington Post and reported a disturbing story of Washington at its worst - about an act of Congress that crippled the DEA's ability to fight the worst drug ...